The role of robotics in lung transplantation is gaining attention, but its clinical value remains under debate. During the 46th Annual Meeting of the International Society for Heart and Lung Transplantation in Toronto, leading surgeons discussed both the potential and the limitations of robotic-assisted procedures in this complex field.
The session brought together contrasting perspectives from Stephanie Chang of NYU Langone Health and Hermann Reichenspurner, a pioneer in minimally invasive surgery. Their debate reflects a broader question within healthcare: does advanced technology translate into better patient outcomes?
Less invasive, broader access
Proponents of robotic-assisted thoracic surgery highlight its potential to reduce the physical burden of transplantation. According to Chang, robotic techniques allow for smaller incisions, improved visualization, and greater surgical precision. These factors may lead to reduced blood loss, fewer complications, and shorter hospital stays.
Importantly, she argues that such benefits could expand access to transplantation. “As procedures become less invasive and more efficient, older and more vulnerable patients may become eligible for transplant,” Chang noted during the session.
This aligns with a broader trend in surgery, where minimally invasive approaches are increasingly used to improve recovery times and patient experience.
Evidence gap and cost concerns
However, not all experts are convinced that robotics currently offers clear clinical advantages. Reichenspurner emphasized the lack of robust evidence supporting superior outcomes. “There is no comparative study demonstrating significant improvements in survival, complications, or length of stay,” he stated.
He also pointed to the high costs associated with robotic systems, including acquisition, maintenance, and training. These factors may limit access to well-funded centers and raise questions about cost-effectiveness.
In addition, the absence of randomized controlled trials makes it difficult to integrate robotic approaches into international clinical guidelines. Reichenspurner warned that in some cases, robotics risks being used as a marketing tool rather than a necessity driven by patient benefit.
Innovation requires evidence
Despite differing views, both experts agree that robotics will likely play a growing role in lung transplantation, particularly in centers already experienced with robotic thoracic procedures. The technology also offers clear advantages in surgical training, allowing instructors and trainees to operate simultaneously with enhanced precision.
Yet, for widespread adoption, stronger clinical validation will be essential. As Reichenspurner concluded, randomized studies comparing robotic and minimally invasive techniques are needed to determine whether the added complexity and cost are justified.
For now, robotic lung transplantation remains a promising but still evolving innovation, one that must balance technological advancement with evidence-based care.
